Nu Skin is rated a buy, trading at low multiples with turnaround prospects tied to India expansion and Prysm iO device launch. NUS's core MLM business faces structural decline, but new product and market initiatives could stabilize or grow revenue beyond 2026. Prysm iO potential subscription fees may provide incremental revenue not fully reflected in current guidance.









